Results 241 to 250 of about 6,414,902 (294)

Long‐Term Follow‐Up of Chemotherapy‐Associated Biological Aging in Women With Early Breast Cancer

Aging and Cancer, EarlyView.
Women threated with adjuvant chemotherapy for early breast cancer have sustained long‐term increase in p16INK4a,, a robust marker of cell senescence, suggesting a chemotherapy‐associated age acceleration. p16INK4a as well as other biomarkers may identify patients at greatest risk for senescence‐related diseases of aging.
Hyman B. Muss, Alexis C. Wardell, Allison M. Deal, Kirsten A. Nyrop, Allison Ross, Yara G. Abdou, Jeffrey D. Aldrich, Lisa A. Cary, E. Claire Dees, Katherine E. Reeder‐Hayes, Emily M. Ray, Natalia Mitin, Denis Tsygankov   +12 more
wiley   +1 more source

Recurrence of minimal residual disease in acute myeloid leukemia: a window of opportunity for intervention. [PDF]

Haematologica
Bankar A.
europepmc   +1 more source

Detection and Monitoring of Breast Cancer Local Recurrence Via Circulating Tumor DNA Minimal Residual Disease Assay. [PDF]

JCO Precis Oncol
Prasath V, Jhawar SR, To B, Mestres-Villanueva MA, Schneider BP, Reátegui E, Stover DG.   +6 more
europepmc   +1 more source

t(11;14) multiple myeloma patient: minimal residual disease after 10 years of follow-up - a case report. [PDF]

Haematologica
Decheiver S, Schavgoulidze A, Maheo S, Vion PA, Lucidarme O, Corre J, Garderet L.   +6 more
europepmc   +1 more source

Dynamic Phosphoproteomic Profiling Identifies Casein Kinase 2 as a Critical Survival Kinase in Quiescent Breast Cancer Cells and a Potential Therapeutic Target for Minimal Residual Disease. [PDF]

Cancers (Basel)
Csergeová L, Janoštiak R.
europepmc   +1 more source

Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma. [PDF]

Future Oncol
Gordan LN, Warner A, Heritage T, Ming A, Gupta-Werner N, Kaila S, Cortoos A.   +6 more
europepmc   +1 more source

Tandem autologous stem cell transplant in multiple myeloma patients with minimal residual disease: an explorative study. [PDF]

Blood Res
Oh S, Park SS, Lee JY, Yoon JH, Lee SE, Kim HJ, Shin SH, Jeon YW, Yahng SA, Jung J, Ahn A, Kim M, Min CK.   +12 more
europepmc   +1 more source

Cytogenetic monitoring of minimal residual disease and autologous bone marrow transplantation (ABMT)

, 1990
Porta F., Burgio G. R., MASERATI, EMANUELA, Bonetti F., Truglio F., PASQUALI, FRANCESCO, Giani S., Locatelli F., Nespoli L., Campagnoli E., Bongiorno M., Gibardi A.   +11 more
core  

Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?

Hematology/Oncology Clinics of North America, 2021
With the advent of highly effective novel therapies for chronic lymphocytic leukemia, conventional response assessment is not able to sensitively capture depth of response.
John Seymour, Arnon Kater, Othman Al-Sawaf   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Detection of minimal residual disease

2001
Publisher Summary Minimal residual disease (MRD) is defined as the presence of a small number of cancer cells in hematological malignancies usually below 1010 cells (that amount approximately corresponds to 1g of the total cancer cell burden in a human body).
A, Deptala, S P, Mayer
openaire   +4 more sources